{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:33:44Z","timestamp":1790487224412,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001127.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T00:00:00Z","timestamp":1459728000000}}],"reference-count":133,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001127.pub3","type":"journal-article","created":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T22:34:55Z","timestamp":1459809295000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Dornase alfa for cystic fibrosis"],"prefix":"10.1002","author":[{"given":"Connie","family":"Yang","sequence":"first","affiliation":[{"name":"BC Children's Hospital; Department of Pediatrics, Division of Respiratory Medicine; 4480 Oak Street Vancouver BC Canada V6H 3V4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Chilvers","sequence":"additional","affiliation":[{"name":"BC Children's Hospital; Department of Pediatrics, Division of Respiratory Medicine; 4480 Oak Street Vancouver BC Canada V6H 3V4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Alberta Children's Hospital; Pediatrics and Child Health; 2888 Shaganappi Trail NW Calgary AB Canada T3B 6A8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J","family":"Nolan","sequence":"additional","affiliation":[{"name":"The University of Liverpool; Department of Biostatistics; Block F, Waterhouse Building 1-5 Brownlow Hill Liverpool UK L69 3GL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,4]]},"reference":[{"issue":"Suppl 1","key":"10.1002\/14651858.CD001127.pub3-BIB0001|cit1","first-page":"S66","article-title":"Hypertonic saline X recombinant human DNase: a randomised cross-over study in 18 cystic fibrosis patients [abstract]","volume":"3","author":"Adde","year":"2004","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD001127.pub3-BIB0003|cit2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1183\/09031936.00072510","article-title":"The effect of dornase alfa on ventilation in homogeneity in patients with cystic fibrosis","volume":"37","author":"Amin","year":"2011","journal-title":"European Respiratory Journal"},{"issue":"Suppl 33","key":"10.1002\/14651858.CD001127.pub3-BIB0002|cit3","first-page":"361, Abstract n","article-title":"The effect of dornase alfa on ventilation in homogeneity in patients with cystic fibrosis [abstract]","volume":"45","author":"Amin","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0005|cit4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1569-1993(01)00009-1","article-title":"Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis","volume":"1","author":"Ballmann","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0004|cit5","doi-asserted-by":"crossref","unstructured":"Ballmann M von der Hardt H Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract] 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany 1998 80","DOI":"10.1016\/S1569-1993(01)00009-1"},{"issue":"Suppl 32","key":"10.1002\/14651858.CD001127.pub3-BIB0006|cit6","first-page":"357, Abstract n","article-title":"Effects of nebulized recombinant human deoxyribonuclease (dornase alfa) in infants with CF evaluated using infant pulmonary function testing and high resolution computerized tomographic imaging of the chest [abstract]","volume":"32","author":"Castile","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0007|cit7","unstructured":"NCT00179998 Efficacy of Pulmozyme in infants and young children with cystic fibrosis http:\/\/clinicaltrials.gov\/show\/NCT00179998 2005"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0008|cit8","unstructured":"Dodd ME Moorcroft AJ Haworth CS Francis S Miles J Clayton N The effect of rhDNase on exercise performance and gas trapping in adults with cystic fibrosis: a randomised controlled trial [abstract] Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm 2000 147"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0009|cit9","first-page":"246","article-title":"Effect of aerosolised or rhDNase (Pulmozyme\u00ae) on pulmonary infections in CF: an open randomised study (abstract)","volume":"Suppl 20","author":"Frederiksen","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD001127.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/08035250600752466","article-title":"Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis","volume":"65","author":"Frederiksen","year":"2006","journal-title":"Acta Paediatrica"},{"issue":"7","key":"10.1002\/14651858.CD001127.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/0929-693X(96)81225-5","article-title":"Clinical development of rhDNase in the United States","volume":"2","author":"Eisenberg","year":"1995","journal-title":"Archives de Pediatrie"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0012|cit12","unstructured":"Fuchs HJ Borowitz D Christiansen D Morris E Nash M Ramsey B Aerosolised recombinant human DNase reduces pulmonary exacerbations and improves pulmonary function in patients with cystic fibrosis [abstract] Proceedings of the 36th Annual Conference on Chest Disease; 1993 1993"},{"issue":"10","key":"10.1002\/14651858.CD001127.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1017\/S0266462300009387","article-title":"A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis","volume":"12","author":"Menzin","year":"1996","journal-title":"International Journal of Technology Assessment in Healthcare"},{"issue":"5","key":"10.1002\/14651858.CD001127.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/106002809502900501","article-title":"Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis","volume":"29","author":"Oster","year":"1995","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0016|cit16","first-page":"152","article-title":"A summary of the results of the phase III multicenter clinical trial: aerosol administration of recombinant human DNase reduces the risk of respiratory tract infections and improves pulmonary function in patients with cystic fibrosis [abstract]","volume":"Suppl 9","author":"Ramsey B for the Pulmozyme (rhDNase) Study Group","year":"1993","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD001127.pub3-BIB0017|cit17","first-page":"220","article-title":"Socioeconomic evaluation of the influence of rhDNase on the costs of treating respiratory tract infections in patients with cystic fibrosis","volume":"90","author":"Schulenburg","year":"1995","journal-title":"Medizinische Klinik"},{"issue":"2","key":"10.1002\/14651858.CD001127.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1164\/ajrccm.153.2.8564129","article-title":"Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis","volume":"153","author":"Laube","year":"1996","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0019|cit19","first-page":"155","article-title":"A randomized, placebo-controlled trial of the effect of recombinant human DNase (rhDNase) on the deposition homogeneity and mucociliary clearance of radioaerosol in patients with cystic fibrosis [abstract]","volume":"Suppl 9","author":"Laube","year":"1993","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0020|cit20","unstructured":"McCoy K for the Pulmozyme Severe Lung Disease Study Group rhDNase is well tolerated and effective in cystic fibrosis patients with severe obstructive ling disease [abstract] Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium 1995 L41"},{"issue":"4","key":"10.1002\/14651858.CD001127.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1378\/chest.110.4.889","article-title":"Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease","volume":"110","author":"McCoy","year":"1996","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/thx.2009.116970","article-title":"Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial","volume":"65","author":"Minasian","year":"2010","journal-title":"Thorax"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD001127.pub3-BIB0023|cit23","first-page":"301","article-title":"A crossover comparative study of inhaled mannitol, alone and in combination with daily rhDNase, in children with cystic fibrosis [abstract]","volume":"43","author":"Minasian","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1465-9921-6-133","article-title":"Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients","volume":"6","author":"Griese","year":"2005","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0025|cit25","unstructured":"Jung A Shute JK Chen CIU Ballmann M Griese M Ratjen F Influence of long-term inhaled rhDNase on free and total IL-8 concentration in BAL fluid in cystic fibrosis [abstract] Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm 2002 P3285"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0026|cit26","first-page":"310","article-title":"Effect of rhDNase on endobronchial inflammation in CF patients with mild lung disease: results of multi-center beat study [abstract]","volume":"Suppl 24","author":"Paul","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD001127.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1164\/rccm.200307-959OC","article-title":"Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis","volume":"169","author":"Paul","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0028|cit28","first-page":"383","article-title":"Airway inflammation in CF patients with good pulmonary function - baseline data from the multicenter \"Beat\" study [abstract]","volume":"Suppl 17","author":"Paul","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0029|cit29","unstructured":"Paul KP Rietschel E Ballmann M Griese M Chen CI Schink T Longitudinal Evaluation of Airway Inflammation in Stable Cystic Fibrosis (CF) Patients by Bronchoalveolar Lavage (BAL) and Influence rhDNase [abstract] American Thoracic Society International Conference; 2003 May 16-21; Seattle, USA. 2003 Poster E42"},{"issue":"Suppl 28","key":"10.1002\/14651858.CD001127.pub3-BIB0030|cit30","first-page":"143","article-title":"Dornase alpha in pediatric CF patients with normal lung function - effects on airway inflammation [abstract]","volume":"40","author":"Ratjen","year":"2005","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0031|cit31","first-page":"310","article-title":"Treatment with rhDNase reduces DNA levels in BAL fluid of CF patients with mild lung disease [abstract]","volume":"Suppl 24","author":"Ratjen","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ppul.20134","article-title":"DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: Influence of treatment with dornase alpha","volume":"39","author":"Ratjen","year":"2005","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0033|cit33","first-page":"318","article-title":"High-resolution CT is more sensitive to longitudinal decline in lung status in young children with CF than pulmonary function tests [abstract]","volume":"Suppl 25","author":"Brody","year":"2003","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD001127.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ppul.20088","article-title":"Dornase alpha and exhaled NO in cystic fibrosis","volume":"38","author":"Grasemann","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0035|cit35","first-page":"299","article-title":"A randomized, placebo-controlled trial of two years' treatment with dornase alfa (Pulmozyme\u00ae) in cystic fibrosis patients aged 6-10 years with early lung disease [abstract]","volume":"Suppl 20","author":"Konstan","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD001127.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1067\/mpd.2001.118570","article-title":"A two-year randomized, placebo controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities","volume":"139","author":"Quan","year":"2001","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD001127.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ppul.10136","article-title":"Dornase alfa in early cystic fibrosis lung disease","volume":"34","author":"Robinson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1164\/ajrccm\/148.1.145","article-title":"Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis","volume":"148","author":"Ramsey","year":"1993","journal-title":"American Review of Respiratory Disease"},{"issue":"8865","key":"10.1002\/14651858.CD001127.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0140-6736(93)92297-7","article-title":"Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis","volume":"342","author":"Ranasinha","year":"1993","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0040|cit40","unstructured":"Ranasinha C Empey D Geddes D Fuchs H Hodson ME A phase 2 double-blind placebo controlled study of the pulmonary function and the safety of aerosolised recombinant human DNase in adults with stable stage cystic fibrosis [abstract] Proceedings of the 11th International Cystic Fibrosis Congress; 1992 1992 LBS5"},{"issue":"2","key":"10.1002\/14651858.CD001127.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/thx.51.2.119","article-title":"In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis","volume":"51","author":"Shah","year":"1996","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0042|cit42","first-page":"273","article-title":"Effect of short course of rhDNase on mucociliary clearance in patients with cystic fibrosis [abstract]","volume":"Suppl 14","author":"Hemming","year":"1997","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/1099-0496(200007)30:1<16::AID-PPUL4>3.0.CO;2-H","article-title":"Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis","volume":"30","author":"Robinson","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0044|cit44","first-page":"298","article-title":"Composite CT\/PFT score: an outcome measure which markedly improves sensitivity to change in early cystic fibrosis lung disease [abstract]","volume":"Suppl 24","author":"Robinson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD001127.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1378\/chest.128.4.2327","article-title":"Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis","volume":"128","author":"Robinson","year":"2005","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD001127.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1164\/rccm.200209-1093OC","article-title":"Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease","volume":"168","author":"Robinson","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"7","key":"10.1002\/14651858.CD001127.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0929-693X(96)81226-7","article-title":"Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement","volume":"2","author":"Hodson","year":"1995","journal-title":"Archives de Pediatrie"},{"issue":"6","key":"10.1002\/14651858.CD001127.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1183\/09031936.95.08060954","article-title":"Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment","volume":"8","author":"Shah","year":"1995","journal-title":"European Respiratory Journal"},{"issue":"Suppl 19","key":"10.1002\/14651858.CD001127.pub3-BIB0049|cit49","first-page":"574S","article-title":"Scanning electron microscopy of cystic fibrosis sputum [abstract]","volume":"8","author":"Shah","year":"1995","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0050|cit50","first-page":"157","article-title":"Report on a multicentre study using aerosolised recombinant human DNase I in the treatment of cystic fibrosis patients with severe pulmonary disease [abstract]","volume":"Suppl 9","author":"Shah","year":"1993","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 19","key":"10.1002\/14651858.CD001127.pub3-BIB0051|cit51","first-page":"574S","article-title":"The effects of recombinant human DNase I on sputum DNA content [abstract]","volume":"8","author":"Shah","year":"1995","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S0266462303000072","article-title":"A cost-effectiveness analysis of rhDNase in children with cystic fibrosis","volume":"19","author":"Grieve","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"10","key":"10.1002\/14651858.CD001127.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/thorax.57.10.841","article-title":"Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis","volume":"57","author":"Suri","year":"2002","journal-title":"Thorax"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001127.pub3-BIB0054|cit54","first-page":"iii84","article-title":"Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis [abstract]","volume":"56","author":"Suri","year":"2001","journal-title":"Thorax"},{"issue":"3","key":"10.1002\/14651858.CD001127.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1164\/rccm.2110015","article-title":"Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis","volume":"166","author":"Suri","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0056|cit56","first-page":"281","article-title":"Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]","volume":"Suppl 22","author":"Suri","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0057|cit57","first-page":"A75","article-title":"A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis [abstract]","volume":"55","author":"Suri","year":"2000","journal-title":"Thorax"},{"issue":"9290","key":"10.1002\/14651858.CD001127.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(01)06412-1","article-title":"Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial","volume":"358","author":"Suri","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD001127.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.rmed.2006.05.012","article-title":"Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial","volume":"101","author":"Suri","year":"2007","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ppul.10442","article-title":"Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis","volume":"37","author":"Suri","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0062|cit61","first-page":"125","article-title":"In vivo use of hypertonic saline in CF [abstract]","volume":"Suppl 20","author":"Suri","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0061|cit62","doi-asserted-by":"crossref","unstructured":"Suri R Wallis C Bush A Thompson S Normand C Flather M A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis Health Technology Assessment (HMSO) 2002","DOI":"10.3310\/hta6340"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0063|cit63","first-page":"154","article-title":"A phase II, double blind, multicenter study of the safety and efficacy of aerosolized recombinant human DNase I in hospitalized patients with CF experiencing acute pulmonary exacerbations [abstract]","volume":"Suppl 9","author":"Wilmott R and the DNase Multicenter Study Group and Genentech staff","year":"1993","journal-title":"Pediatric Pulmonology"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD001127.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1164\/ajrccm.153.6.8665055","article-title":"Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations","volume":"153","author":"Wilmott","year":"1996","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"S74, Abstract n","DOI":"10.1016\/S1569-1993(09)60294-0","article-title":"Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with cystic fibrosis [abstract]","volume":"8 Suppl 2","author":"Anderson","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"S62, Abstract n","DOI":"10.1016\/S1569-1993(10)60240-8","article-title":"Efficacy of peripheral deposition of inhaled rhDNase in CF patients during a respiratory tract infection [abstract]","volume":"9 Supplement 1","author":"Bakker","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S33","key":"10.1002\/14651858.CD001127.pub3-BIB0067|cit67","first-page":"306, Abstract n","article-title":"Peripheral versus central deposition of inhaled rhdnase in children with cystic fibrosis [abstract]","volume":"45","author":"Bakker","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S19, Abstract n","DOI":"10.1016\/S1569-1993(11)60093-3","article-title":"Small airways response to dornase alfa improves using controlled inhalation: a randomized controlled trial in cystic fibrosis patients [abstract]","volume":"10 Supplement 1","author":"Beukel-Bakker","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1183\/09031936.99.13105399","article-title":"Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group.","volume":"13","author":"Bollert","year":"1999","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0070|cit70","first-page":"204","article-title":"Targeted introduction of DNase in Scotland [abstract]","volume":"Suppl 12","author":"Bollert","year":"1995","journal-title":"Pediatric Pulmonology"},{"issue":"12","key":"10.1002\/14651858.CD001127.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archotol.131.12.1097","article-title":"Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease","volume":"131","author":"Cimmino","year":"2005","journal-title":"Archives of Otolaryngology - Head and Neck Surgery"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0072|cit72","unstructured":"Craig T Pulmozyme in cystic fibrosis with sinusitis clinicaltrials.gov\/ct2\/show\/NCT01155752"},{"issue":"3","key":"10.1002\/14651858.CD001127.pub3-BIB0073|cit73","first-page":"A72","article-title":"Randomized multicentric double blind study of safety and efficacy of Nacystelyn DPI versus placebo in rhDNase treated cystic fibrosis patients [abstract]","volume":"161","author":"Dab","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0074|cit74","unstructured":"Malfroot A Dab I Baran D App EM Coffiner M Nagy AM Randomised multicentric double blind study of tolerability and efficacy of a DPI Nacystelyn versus placebo in cystic fibrosis patients treated by rhDNase for at least 3 months [abstract] Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden 2000 146"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0075|cit75","first-page":"244","article-title":"Randomized multicentric double blind study of tolerability and efficacy of a DPI Nacystelyn versus placebo in cystic fibrosis patients treated by rhDNase for at least 3 months [abstract]","volume":"Suppl 19","author":"Malfroot","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0076|cit76","unstructured":"Diot P RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00843817"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1569-1993(06)80164-5","article-title":"Comparison of Pari LC-Star and -Plus nebulisers delivering 2.5mg recombinant human deoxyribonuclease (rhDNase) [abstract]","volume":"5 Suppl","author":"Elkins","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD001127.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1542\/peds.2005-0308","article-title":"A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis","volume":"116","author":"Fitzgerald","year":"2005","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0079|cit79","first-page":"309","article-title":"Is dornase alfa (pulmozyme) more effective before or after physiotherapy? A cross-over, randomised placebo controlled trial [abstract]","volume":"Suppl 22","author":"Fitzgerald","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0080|cit80","first-page":"310","article-title":"Dornase alpha and physiotherapy - which should be first? A randomised double-blind, placebo-controlled trial in CF adults [abstract]","volume":"Suppl 22","author":"Middleton","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0081|cit81","unstructured":"Genentech Inc A study of Pulmozyme\u00ae (dornase alpha) in 3- to 5-year-old patients with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT00680316"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0188-4409(00)00258-7","article-title":"Efficacy of human recombinant DNase in pediatric patients with cystic fibrosis","volume":"32","author":"Furuya","year":"2001","journal-title":"Archives of Medical Research"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0083|cit83","unstructured":"Genentech Inc A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects with Severe Lung Disease (TOPIC) https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00434278"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/pupt.1997.0072","article-title":"Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum","volume":"10","author":"Griese","year":"1997","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001127.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1569-1993(08)60103-4","article-title":"Direct dispensing of dornase alpha improves adherence and lung function in cystic fibrosis [abstract]","volume":"7","author":"Hagelberg","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD001127.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0300-2977(95)00022-F","article-title":"Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients","volume":"46","author":"Heijerman","year":"1995","journal-title":"The Netherlands Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD001127.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM199203193261207","article-title":"A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis","volume":"326","author":"Hubbard","year":"1992","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0088|cit88","unstructured":"Johnson JC Waldrep JC Dhand R Aerosol delivery of recombinant human DNase 1. Comparison of a vibrating mesh nebulizer with a jet nebulizer [abstract] American Thoracic Society International Conference; 2006 May 19-24; California, USA 2006 A82"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1164\/ajrccm.156.1.9512074","article-title":"Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I","volume":"156","author":"King","year":"1997","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0090|cit90","unstructured":"Lahiri T Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00416182?term=nct00416182&rank=1 accessed 14 April 2015"},{"issue":"11","key":"10.1002\/14651858.CD001127.pub3-BIB0091|cit91","first-page":"1438","article-title":"Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis","volume":"50","author":"Laube","year":"2005","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0092|cit92","first-page":"247","article-title":"Positive expiratory pressure alters aerosol distribution in CF [abstract]","volume":"Suppl 20","author":"Laube","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD001127.pub3-BIB0093|cit93","first-page":"305","article-title":"Double-blind, placebo-controlled pilot trial on sinonasal inhalation of dornase alfa in CF [abstract]","volume":"43","author":"Mainz","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001127.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1569-1993(08)60104-6","article-title":"Sinu-nasal inhalation of Dornase alfa in CF. Results of a double-blind placebo-controlled pilot trial [abstract]","volume":"7","author":"Mainz","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001127.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"S23, Abstract n","DOI":"10.1016\/S1569-1993(10)60089-6","article-title":"Sinonasal inhalation of dornase alfa reduces rhinosinusitis symptoms in CF. Results of a DBPC-cross-over-study [abstract]","volume":"9","author":"Mainz","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0096|cit96","first-page":"308","article-title":"Reduction in sputum viscosity using high frequency chest compressions (HFCC) compared to conventional chest physiotherapy (CCP) [abstract]","volume":"Suppl 13","author":"Majaesic","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD001127.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ppul.1061","article-title":"Use of computerized tomography and chest-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than 5 years : A preliminary study","volume":"31","author":"Nasr","year":"2001","journal-title":"Pediatric Pulmology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0098|cit98","first-page":"278","article-title":"Aerolized recombinant human DNase in cystic fibrosis patients younger than 5 years of age [abstract]","volume":"Suppl 19","author":"Nasr","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD001127.pub3-BIB0099|cit99","first-page":"361","article-title":"Comparison of the delivery characteristics of Dornase alfa from the I-NEB AAD system and the sidestream jet nebulizer [abstract]","volume":"43","author":"Potter","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ppul.20298","article-title":"Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children","volume":"41","author":"Riethmueller","year":"2006","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0101|cit101","first-page":"298","article-title":"Quantitative HRCT air trapping analysis in CF subjects with mild lung disease during a pulmozyme intervention study [abstract]","volume":"Suppl 24","author":"Robinson","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0102|cit102","first-page":"452, Abstract n","article-title":"A study to evaluate the comparable efficacy and safety of Pulmozyme\u00ae delivered by the Erapid\u2122 nebulizer system [abstract]","volume":"48 Suppl 36","author":"Konstan","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD001127.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2015.04.003","article-title":"Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients","volume":"14","author":"Sawicki","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0104|cit104","first-page":"445-446, Abstra","article-title":"Impact of dornase alfa delivered by the eRapid\u2122 vs. Pari LC\u00ae plus jet nebulizer system on cystic fibrosis-related quality of life - results from the IMPART Study [abstract]","volume":"49 Suppl 38","author":"Sawicki","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0105|cit105","first-page":"444, Abstract n","article-title":"Treatment preferences and satisfaction with dornase alfa delivered by the eRapid\u2122 vs. Pari LC\u00ae plus jet nebulizer system to patients with cystic fibrosis - results from the IMPART Study [abstract]","volume":"49 Suppl 38","author":"Sawicki","year":"2014","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD001127.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0954-6111(95)90126-4","article-title":"Two years of experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis","volume":"89","author":"Shah","year":"1995","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD001127.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/thx.50.4.333","article-title":"Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I","volume":"50","author":"Shah","year":"1995","journal-title":"Thorax"},{"issue":"Suppl","key":"10.1002\/14651858.CD001127.pub3-BIB0108|cit108","first-page":"S222","article-title":"An evaluation of two aerosol delivery systems for rhDNase [abstract]","volume":"32","author":"Shah","year":"1996","journal-title":"Israel Journal of Medical Sciences"},{"issue":"6","key":"10.1002\/14651858.CD001127.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1183\/09031936.97.10061261","article-title":"An evaluation of two aerosol delivery systems for rhDNase","volume":"10","author":"Shah","year":"1997","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD001127.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1569-1993(03)00090-0","article-title":"DNase in stable cystic fibrosis infants: a pilot study","volume":"2","author":"Berge","year":"2003","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001127.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1569-1993(09)60004-7","article-title":"Does the timing of inhaled dornase alfa matter?","volume":"8","author":"Giessen","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0112|cit112","first-page":"S97","article-title":"Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis [abstract]","volume":"4 Suppl","author":"Giessen","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"issue":"7","key":"10.1002\/14651858.CD001127.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ppul.20636","article-title":"RhDNase before airway clearance therapy improves airway patency in children with CF","volume":"42","author":"Giessen","year":"2007","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0114|cit114","first-page":"285","article-title":"Efficacy of DNase in individual children using the N-of-1 study design [abstract]","volume":"Suppl 19","author":"Weck","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"12","key":"10.1002\/14651858.CD001127.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/ppul.20704","article-title":"Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial","volume":"42","author":"Wilson","year":"2007","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0116|cit116","unstructured":"Cho Eva Cost of medications [personal communication] Email to: C Yang"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD001127.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health","volume":"176","author":"Flume","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD001127.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0120|cit120","unstructured":"Higgins JPT Altman DG on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors) Chapter 8: \u00a0Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD001127.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1378\/chest.07-2294","article-title":"Inhaled mannitol improves lung function in cystic fibrosis","volume":"133","author":"Jaques","year":"2008","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1740774508100984","article-title":"Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials","volume":"6","author":"Jones","year":"2009","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jama.1968.03140310070022","article-title":"Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis","volume":"205","author":"Lierberman","year":"1968","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"10.1002\/14651858.CD001127.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1017\/S0266462300009387","article-title":"A multi national economic evaluation of rhDNase in the treatment of cystic fibrosis","volume":"12","author":"Menzin","year":"1996","journal-title":"International Journal of Technology Assessment in Healthcare"},{"key":"10.1002\/14651858.CD001127.pub3-BIB0125|cit125","unstructured":"National Institute for Health and Clinical Excellence Mannitol dry powder for inhalation for treating cystic fibrosis www.nice.org.uk\/guidance\/ta266\/documents\/cystic-fibrosis-mannitol-final-appraisal-determinaton3 Oct 2012 1 62"},{"issue":"5","key":"10.1002\/14651858.CD001127.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/106002809502900501","article-title":"Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis","volume":"29","author":"Oster","year":"1995","journal-title":"Annals of Pharmacotherapy"},{"issue":"2","key":"10.1002\/14651858.CD001127.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD001127.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1164\/rccm.200901-0069OC","article-title":"Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening","volume":"180","author":"Sly","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD001127.pub3-BIB0129|cit129","first-page":"220","article-title":"Socioeconomic evaluation of the influence of rhDNase on the costs of treating respiratory tract infections in patients with cystic fibrosis","volume":"90","author":"Schulenburg","year":"1995","journal-title":"Medizinische Klinik"},{"issue":"2","key":"10.1002\/14651858.CD001127.pub3-BIB0130|cit130","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001506.pub3","article-title":"Nebulised hypertonic saline for cystic fibrosis","author":"Wark","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001127.pub3-BIB0131|cit131","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001127","article-title":"Recombinant human deoxyribonuclease for cystic fibrosis","author":"Jones","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001127.pub3-BIB0132|cit132","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001127","article-title":"Dornase alfa for cystic fibrosis","author":"Jones","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD001127.pub3-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001127","article-title":"Deoxyribonuclease for cystic fibrosis","author":"Kearney","year":"1998","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001127.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD001127.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T13:28:39Z","timestamp":1692278919000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001127.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,4,4]]},"references-count":133,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001127.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD001127.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,4]]}}}